|
|
||||||||
Ann Thorac Surg 1999;67:79-84
© 1999 The Society of Thoracic Surgeons
a Department of Cardiovascular Surgery, Jichi Medical School, Tochigi, Japan
b Department of Clinical Pharmacology, Jichi Medical School, Tochigi, Japan
c Omiya Medical Center, Jichi Medical School, Saitama, Japan
Accepted for publication June 16, 1998.
Address reprint requests to Dr Kawahito, Department of Cardiovascular Surgery, Jichi Medical School, Yakushiji, Minami-Kawachi, Kawachi, Tochigi 329-04, Japan
e-mail: bza06625{at}niftyserve.or.jp
| Abstract |
|---|
|
|
|---|
Methods. Nineteen patients undergoing CPB were evaluated. Blood samples were obtained before the operation, 1 hour after initiation of CPB, at the end of CPB, at the end of the operation, and on day 1 after the operation. Platelet aggregation after stimulation by 2.5 µmol/L adenosine diphosphate and 2.0 µg/mL collagen was determined; small (9 to 25 µm), medium (25 to 50 µm), and large (50 to 70 µm) aggregates were counted.
Results. Generation of medium and large aggregates after stimulation with adenosine diphosphate and collagen were significantly decreased with CPB, whereas, in spite of hemodilution, the quantity of the small aggregates was maintained at the elevated level.
Conclusions. These results reflect the fact that CPB does not affect the first phase of aggregation. It suggests that platelet dysfunction associated with CPB is mainly caused by an inhibition in the development of small aggregates into larger aggregates.
| Introduction |
|---|
|
|
|---|
Although platelet aggregation is conventionally evaluated using optical density (OD) changes [11] or impedance analysis [12], these methods do not provide information about temporal changes in the numbers of platelet aggregates of different sizes after stimulation with an aggregation agent. Furthermore, the assumption that platelet aggregation evaluated by OD methods is reflective of in vivo hemostatic function is controversial [3, 13, 14]. The light-scattering (LS) method, which resembles that used in the flow cytometric light-scattering technique, enables selective detection of scattered light from a single aggregate in a defined observation volume. The intensity of scattered light corresponds to particle size and provides greater sensitivity than the OD method. Newly developed particle-counting methods that use light scattering (AG-10 aggregometer; Cowa Co Ltd, Tokyo, Japan) are being used to quantify real-time changes in the number of platelet aggregates of different sizes after the application of an aggregating stimulus [1517]. This new system makes possible sensitive, continuous in situ evaluations of aggregation by counting and sizing aggregates. Using this system, we quantified aggregates of different sizes after stimulation with aggregating agents and observed their changes with time in patients undergoing cardiac operations.
| Material and methods |
|---|
|
|
|---|
All received a similar balanced anesthesia, including high-dose sulfentanyl citrate and a neuromuscular blocking agent. All CPB procedures were done at moderate hypothermia (25° to 30°C) with cold-blood cardioplegia. The CPB system included a roller pump (Stöckert Instruments, Munich, Germany), a cardiotomy reservoir (William/Harvey; Bard, Tewksbury, MA), and a membrane oxygenator (Affinity, Avecor, Plymouth, MN). Bypass tubing included of standard silicone rubber components and polycarbonate connectors. The extracorporeal circuit was primed with crystalloid solution. Before cannulation, patients received heparin at a dose of 2.5 mg/kg body weight. Activated clotting time was maintained for more than 450 seconds during the CPB. Bypass was conducted at a flow rate of 2.4 L · min-1 · m-2, and mean arterial pressure was maintained at 50 to 70 mm Hg. After initiation of CPB, lung ventilation was discontinued and was subsequently resumed at the end of the period of aortic cross-clamping. After discontinuation of CPB, heparin was neutralized with protamine sulfate.
The duration of cardioplegic arrest varied from 25 to 164 minutes (mean, 100 ± 42 minutes), and CPB times ranged from 89 to 239 minutes (mean, 151 ± 44 minutes).
Platelet aggregation studies
Platelet-rich plasma (PRP) aggregation was simultaneously determined by evaluating maximal percent decrease in OD and by assessing the LS intensity using the AG-10 aggregometer. In the OD method, the output from the aggregometer was adjusted so that the difference in light transmittance between the PRP and the platelet-poor plasma (PPP) was 100%. Using the LS method, variations in particle size and concentration in PRP are measured by detecting the respective scattered light intensities passing through a laser beam. The principles of the LS method have been described previously [1517]. Briefly, a He-Ne laser beam with a diameter of 40 µm was passed through 300 µm of PRP rotated in a cylindrical glass cuvette with a 5-mm internal diameter. Light scattered from the observation volume (48 x 140 x 20 µm) was detected with a four-channel photodiode array, with light intensity corresponding to particle size. Each of the four photodiodes detected the light-scattering particles in its corresponding observation volume (one photodiode for each observation volume). The intensity of the scattered light in the direction perpendicular to the optical axis from a particle passing through a laser beam is detected by a photodiode array through an objective lens and it is described as the millivolts. According to the algorithm derived by Lentz from the Mie scattering theory [18], the relationship between the scattered light intensity, I, and the particle size, d, is approximately represented as I = Kd2, where K is a constant that specifies the value of scattered light intensity corresponding to a certain particle size. After eliminating high-frequency noise from the output signal using low-pass filters with a cut-off frequency of 10 kHz, the amplitudes and frequency of alternating current signals were analyzed on a personal computer (PC-98 As2; NEC, Tokyo, Japan). The signal frequency was recorded at 10-second intervals.
Data were expressed as the change with time in the number of aggregates of each of three sizes (determined by light intensity, expressed in millivolts). The total light intensities of small, medium, and large aggregates were determined as follows. Particles with an intensity of 25 to 400 mV were counted as small aggregates (9 to 25 µm); an intensity of 400 to 1,000 mV indicated medium aggregates (25 to 50 µm); and an intensity of 1,000 to 2,048 mV indicated large aggregates (50 to 70 µm). Data were recorded on a two-dimensional graph showing the change with time of total light intensity expressed as a cumulative summation at 10-second intervals of scattered light intensity (Ii) and the number of particles corresponding to that intensity (Ni) in terms of particle size (intensity) (S Ii Ni) (volts x counts/10 s). Total intensity was recorded at 10-second intervals for 8 minutes. Quantitative estimation was performed by determining the area under the curve, representing the sum of measurements of the LS intensity.
Measurements
Blood samples from a radial artery catheter were collected at the following observation times: before the operation, 1 hour after initiation of CPB, at the end of CPB (after protamine administration), at the end of the operation, and on day 1 after the operation. For platelet aggregometry, 4.5 mL of whole blood was taken and stored in silicone-coated tubes with 0.5 mL sodium citrate solution. The PRP was obtained by centrifuging whole blood at 120 g for 10 minutes at room temperature and aspirating the supernatant. The PRP was incubated for 3 minutes at 37°C. The PPP was obtained by centrifuging whole PRP at 1,800 g for 10 minutes. Aggregation was induced by addition of 2.5 µmol/L adenosine diphosphate (ADP) and 2 µg/mL collagen (final concentration; Sigma Chemical Co, St. Louis, MO). The solution is constantly stirred by a magnetic bar at a rate of 1,000 rpm.
Aggregation of PRP by assessing the LS intensity was determined simultaneously with the OD method by evaluating maximal percent decrease. Platelet aggregation after stimulation by 2.5 µmol/L ADP and 2.0 µg/mL collagen was determined using both OD and LS methods. Using the LS method, small, medium, and large aggregates were counted. Aggregation curves were recorded for 8 minutes after addition of the agonist. Figure 1 shows the typical aggregation patterns of healthy volunteers measured by LS method and OD method using the Cowa AG-10 aggregometer. After stimulation, small aggregates are formed transiently in the first phase of aggregation, and larger aggregates are formed in the second phase. This fact implies that a progression from small to larger aggregates is the natural course of platelet aggregation.
|
Statistical analysis
All data are presented as mean ± standard deviation. A Wilcoxon matched-pairs signed-ranks test was used for comparisons of values from one variable between two time points. A p value less than 0.05 was considered significant.
| Results |
|---|
|
|
|---|
|
Platelet aggregation pattern measured by light-scattering methods
Figure 2 shows a typical pattern with time in LS intensity detection of small, medium, and large aggregates after stimulation with ADP. Before the operation, small aggregates formed in the first phase of aggregation and larger aggregates formed in the second phase after stimulation. The quantity of small aggregates increased, and larger aggregates increased after that (Fig 2A). Contrary to this, in the samples taken 1 hour after initiation of CPB, LS intensity detection showed small aggregates increasing rapidly and remaining at an elevated level after stimulation with ADP, whereas medium and large aggregates did not increase and were suppressed (Fig 2B). Table 1 shows the analyzed data of each aggregate size. Although the quantification (area under the curve) of small aggregates was not significantly different between samples drawn before the operation and 1 hour after initiation of CPB (366 ± 167 versus 346 ± 142 x 105 mV), large aggregate formation was significantly decreased at 1 hour after initiation of CPB (196 ± 160 versus 73 ± 96 x 105 mV; p < 0.01). The samples taken after CPB showed a similar pattern (Fig 2C). The quantification of small aggregates did not show any difference between before the operation and after CPB (366 ± 167 versus 312 ± 189 x 105 mV), whereas total LS intensities of large aggregates decreased after CPB (196 ± 160 versus 44 ± 85 x 105 mV; p < 0.01) (see Table 1). Figures 2D and 2E showed the aggregation pattern after the operation and at day 1 after the operation, respectively. Generation of large aggregates was recovered at day 1 after the operation (Fig 2E). As shown in Table 1, quantification of large aggregates increased at day 1 after the operation (after CPB versus day 1 after the operation, 44 ± 85 versus 115 ± 103 x 105 mV; p < 0.01).
|
| Comment |
|---|
|
|
|---|
Hemodilution is one of the extrinsic factors that affect platelet aggregation. As shown in Table 1, the platelet count at 1 hour after initiation of CPB was significantly reduced because of hemodilution, and hemodilution continued until 1 day after the operation. However, LS total intensity of large aggregates significantly increased in day 1 after the operation in both ADP and collagen groups compared with after CPB in spite of low platelet concentration (ADP: after CPB versus day 1 after the operation, 44 ± 85 versus 115 ± 103 x 105 mV; collagen: 33 ± 44 versus 133 ± 96 x 105 mV; p < 0.01). These results suggested that platelet activity to form large aggregates was a reflection of their intrinsic factors. Although hemodilution is one of the important extrinsic factors of platelet aggregation, the generation of small aggregates was not suppressed by CPB. These results suggest that reduced activity of platelets to form larger aggregates does not reflect the hemodilution but the intrinsic factors. Also, CPB does not affect the first phase of aggregation, but rather inhibits the development of small aggregates into large aggregates.
As to the mechanisms of platelet aggregation loss with CPB, recent reports have emphasized that CPB induces defects in the platelet surface glycoprotein Ib/IX complex and glycoprotein IIb/IIIa complex [5, 21] in the initial phase of platelet aggregation. However, these findings are still controversial. As our results suggested that the first phase of platelet aggregation was not inhibited, the platelet surface integrin-mediated aggregation activity may not be completely shut down; aggregation potential may be maintained. As Kestin and associates [8] mentioned in their report, other extrinsic factors such as suppressed thrombin activity by high circulating concentrations of heparin, hypothermia, or fibrinolytic activity may partially contribute to the platelet dysfunction, especially to inhibition of the development of small aggregates into larger aggregates.
As to the potential activity of platelets, Zilla and coworkers [22] reported that circulating platelet morphology recovered from initial activation despite the maintenance of CPB in a scanning and transmission electron microscopic analysis, and the initial platelet consumption in CPB is caused by reversible primary rather than irreversible secondary aggregation phenomena. This suggests that platelets may keep their potential activity, and platelet function is not completely shut down. These primed platelets may be activated by other stimulants such as a high shear stress [6, 7], activated leukocytes [19, 23], activated complement system [19], and so on, resulting in aggregation and subsequent blood coagulation. If so, the increased number of small aggregates may partially explain the occurrence of vascular events such as ischemic cerebrovascular accidents after cardiac operations.
As Tohgi and colleagues [17] mentioned in their article, the clinical significance of aggregate size in in vitro aggregation tests is unknown. Whether a similar phenomenon occurs in the in vivo microenvironment of the vascular endothelium is not known. However, the possibility must be considered that circulating platelets during CPB may maintain aggregation activity, which has been shown not to suppress in quantity by the in vitro LS method during CPB in spite of using heparin. Small aggregates may act as very small emboli in vivo by stimulation, or activated platelet particles may play an important role in thromboembolic accidents. It is necessary to consider that platelet function is suppressed, but not completely impaired, during CPB. Furthermore, whether the in vitro aggregate size impacts the in vivo hemostatic platelet function of patients undergoing CPB is unknown. To clarify the relationship between the in vitro aggregation size and in vivo hemostatic platelet function, measurements of thromboxane B2, which is a metabolite shed at the site of bleeding time determination, and
granule packing proteins may be useful. These correlation may explain the clinical hemostatic significance and the aggregation size of platelets in vitro.
The assumption that platelet aggregation per se is reflective of in vivo hemostatic function is controversial [3, 13, 14]. Some researchers reported that aggregation defects predicted postoperative bleeding [3, 13], and others showed a discordance between platelet aggregation using OD method and in vivo hemostatic function of platelets in patients undergoing CPB [14]. As the LS method can determine size and number of aggregates simultaneously at a sensitivity 100 times greater than that of conventional OD method [16], this new methodology may have the potential of shedding new light on these controversies. However, the duration of CPB is known to be one of the important determinants of CPB-induced hemostatic dysfunction in patients undergoing cardiac operations. Although we did not evaluate the impact of the duration of CPB on platelet aggregation assessed by the LS method, measurements obtained immediately before weaning from CPB (before protamine administration) would have allowed for a better assessment of the significance of these in vitro platelet aggregation studies.
In summary, although the generation of medium and large aggregates estimated by LS was significantly decreased with CPB, there was no significant change in the number of small aggregates. Platelet aggregation dysfunction associated with CPB may be caused mainly by an inhibition in the development of small aggregates into larger aggregates.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
Y. Inoue, R. C. H. Lim, and P. Nand Coronary artery bypass grafting in an immune thrombocytopenic purpura patient using off-pump techniques Ann. Thorac. Surg., May 1, 2004; 77(5): 1819 - 1821. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. W. Muriithi, P. R. Belcher, and V. C. Menys Preoperative platelet inhibition and bleeding after cardiopulmonary bypass J. Thorac. Cardiovasc. Surg., March 1, 2003; 125(3): 739 - 739. [Full Text] [PDF] |
||||
![]() |
R. Ascione, M. Caputo, and G. D. Angelini Off-pump coronary artery bypass grafting: not a flash in the pan Ann. Thorac. Surg., January 1, 2003; 75(1): 306 - 313. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. R. Belcher, E. W. Muriithi, P. Wajon, and J. Gibson Postoperative Bleeding After Coronary Artery Bypass Surgery with Cardiopulmonary Bypass * Response Anesth. Analg., November 1, 2002; 95(5): 1466 - 1467. [Full Text] [PDF] |
||||
![]() |
R. Ascione, S. Al-Ruzzeh, K. Amer, and G. D Angelini Subsystem organ function during coronary surgery Perfusion, July 1, 2002; 17(4): 295 - 303. [Abstract] [PDF] |
||||
![]() |
R. Ascione, S. Williams, C. T. Lloyd, T. Sundaramoorthi, A. A. Pitsis, and G. D. Angelini Reduced postoperative blood loss and transfusion requirement after beating-heart coronary operations: A prospective randomized study J. Thorac. Cardiovasc. Surg., April 1, 2001; 121(4): 689 - 696. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. W. Muriithi, P. R. Belcher, S. P. Day, V. C. Menys, and D. J. Wheatley Heparin-induced platelet dysfunction and cardiopulmonary bypass Ann. Thorac. Surg., June 1, 2000; 69(6): 1827 - 1832. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. R. Belcher and V. C. Menys Platelet studies during cardiopulmonary bypass Ann. Thorac. Surg., September 1, 1999; 68(3): 1126 - 1126. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |